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ABSTRACT 
Trazodone Hydrochloride (TRZ) is a well-known chemical compound that is used as an antidepressant that belongs to selective serotonin 
reuptake inhibitors (SARI). TRZ is used as anti-anxiety and sleep-inducing agent. The objective of the present investigation was formulation and 
evaluation of gastroretentive floating tablets of TRZ for prolongation of gastric residence time with a view to deliver the drug at the sustained 
and controlled manner in the gastrointestinal tract. The tablets of TRZ were prepared by direct compression method using gas generating agent 
and different polymer combinations such as hydroxy propyl methylcellulose and xanthan gum, guar gum. The prepared tablets of TRZ were 
evaluated for hardness, thickness, friability, weight variation, drug content uniformity, buoyancy lag time, total floating time, swelling index, in-
vitro dissolution study, etc. All the compositions were resulted in adequate Pharmacopoeial limits. The varying concentration of gas generating 
agent and polymers was found to affect on in-vitro drug release and floating lag time. In vitro drug release of floating gastro retentive tablet of 
TRZ shown that the formulation F7 was found to be the best formulation as it releases 98.89±0.32% TRZ in a controlled manner for an 
extended period of time (up to 12 hrs). The release data was fitted to various mathematical models such as higuchi, korsmeyer-peppas, first 
order and zero order to evaluate the kinetics and mechanism of the drug release.  The Optimized formulation (F7) showed no significant change 
in physical appearance, drug content, floating lag time, in vitro dissolution studies after 75%±5% RH at 40±20C relative humidity for 6 months.  
Prepared floating tablets of TRZ may prove to be a potential candidate for safe and effective controlled drug delivery over an extended period of 
time for gastro retentive drug delivery system. 
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INTRODUCTION 
Rapid gastrointestinal transit could result in incomplete drug 
release from the dosage form above the absorption zone 
leading to diminished efficacy of the administered dose. 
These considerate have led to the development of a 
controlled or sustained delivery system. The main purpose 
for developing these systems was to release the drug slowly 
into the gastrointestinal tract (GIT) and maintain an effective 
drug concentration in the systemic circulation for long time. 
Gastroretentive drug delivery is an approach to prolong 
gastric retention time, thereby targeting site- specific drug 
release in the upper GIT for local and systemic effect. 
Therefore, different approaches have been proposed to 
retain the dosage form in the stomach. These include 
bioadhesive systems, swelling and expanding systems and 
floating systems. Floating drug delivery or hydrodynamically 
balanced systems have a sufficient buoyancy to float over the 
gastric contents and remain buoyant in the stomach without 
affecting the gastric emptying rate for a prolong period [1-4]. 
TRZ is chemically 2-{3-[4-(3-chlorophenyl) piperazin-1-yl] 
propyl}-2H, 3H-[1, 2, 4] triazolo[4,3-a]pyridin-3-one. It is a 
serotonin antagonist and reuptake inhibitor (SARI), which is 
a second generation antidepressant compound belonging to 
the class of phenyl piperazine. It acts as a serotonin agonist 
at high doses and low doses. The drug showing 
antidepressant activity is due to the blockage of serotonin 
reuptake by inhibiting serotonin reuptake pump at the 
presynaptic neuronal membrane. TRZ shows its therapeutic 
actions through 5-HT2A receptors. TRZ also induces anti-
anxiety and sleep inducing effects [5]. It does not have 
similar properties to selective serotonin reuptake inhibitors 
(SSRIs) since its inhibitory effect on serotonin reuptake and 
5-HT2C receptors are relatively weak [6]. The result of α-
adrenergic action blocking and modest histamine blockade at 
H receptor due to sedative effect of TRZ. It weakly blocks 
presynaptic α2-adrenergic receptors and strongly inhibits 
postsynaptic α1 receptors. TRZ does not show any action on 
the reuptake of norepinephrine or dopamine within the CNS. 
It has fewer anticholinergic side effects than most of the 
tricyclic antidepressants such as dry mouth, constipation and 
tachycardia. TRZ metabolizes to its primary m-chlorophenyl 
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piperazine (mCPP) which is a non selective serotonin 
receptor agonist which might outweigh the benefits of TRZ 
[7-10]. A majority of the investigations on natural excipients 
in drug delivery systems have centered on proteins and 
polysaccharides due to their ability to produce a wide range 
of materials and properties according to molecular structural 
alterations. In recent years, plant gums and mucilages have 
evoked tremendous interest due to their diverse 
pharmaceutical applications such as diluents, binders, 
disintegrants in tablets, thickeners in oral liquids, protective 
colloids in suspensions, gelling agents in gels and bases in 
suppository, thus making them attractive substitutes for 
costly semisynthetic and synthetic excipients. India, due to 
its geographical and environmental positioning, has 
traditionally been a good source for such products among 
the Asian countries [11]. With an aim to improve the 
absorption and oral bioavailability we took an attempt to 
formulate floating drug delivery systems using TRZ as the 
drug candidate employing methocel of various grades like 
K4, K15 and natural polymers like guar gum, xanthan gum. 
MATERIALS AND METHODS 
Materials 
Trazodone HCl were obtained as pure sample from Sun 
Pharmaceutical Industries Ltd. Dewas, as gift samples along 
with their analytical reports. HPMC K15, K4 was obtained 
from Mapromax, Life sciences Pvt. Ltd. Dehradun. Xanthan 
gum, guar Gum, polyvinyl pyrrolidone K 30, lactose and talc 
were purchased from SD Fine Chem. Limited, Mumbai. 
Magnesium stearate, sodium bicarbonate and citric acid 
were purchased from Loba Chemie Pvt. Ltd, Mumbai. All 
other chemical were purchased from Hi Media, Mumbai. 
Double distilled water was prepared freshly and used 
whenever required. All other chemicals used in this study 
including those stated were of analytical reagent (A.R.) 
grade. 
Methods 
Determination of absorption maxima  
A solution of containing the concentration 10μg/ ml was 
prepared in 0.1N HCl. UV spectrum was taken using Double 
beam UV/VIS spectrophotometer (Labindia-3000+). The 
solution was scanned in the range of 200-400nm.  
Preparation calibration curve  
10mg of drug was accurately weighed and dissolved in 10ml 
0.1N HCl in 10 ml volumetric flask, to make (1000 μg/ml) 
standard stock solution (1). Then 1 ml stock solution (1) was 
taken in another 10 ml volumetric flask to make (100μg/ml) 
sub stock solution (2), then final concentrations were 
prepared 5-25μg/ml with 0.1N HCl. The absorbance of 
standard solution was determined using UV/ VIS 
spectrophotometer (Labindia 3000+) at 246.0 nm. Linearity 
of standard curve was assessed from the square of 
correlation coefficient (r2) which determined by least-square 
linear regression analysis. 
Fourier transform infrared (FTIR) spectroscopy 
The physical properties of the physical assortment were 
comparing with those of TRZ pure drug. Samples was 
assorted comprehensively through 100mg potassium 
bromide IR powder as well as compacted under vacuum at a 
pressure of concerning 12 psi for 3 minutes. The ensuing disc 
was mounted in an appropriate holder in Brukers Alpha IR 
spectrophotometer and the IR spectrum was recorded from 
3500 cm to 500 cm. The resultant spectrum was compared 
for any spectrum changes. 
Pre compression evaluation 
Flow properties and compressibility properties of powder 
mixture were evaluated by measurement of angle of repose, 
bulk density, tapped density, carr’s index and hausner’s ratio. 
Angle of repose (θ) 
The angle of repose was determined by using fixed funnel 
method. The physical mixtures of drug with different 
excipients were prepared and the accurately weighed drug 
powder or its physical mixture was taken in a funnel. The 
height of the funnel was adjusted in such a way that the tip of 
the funnel just touches the apex of the heap of the drug 
powder. The powder was allowed to flow through the funnel 
freely onto surface. The angle of repose was calculated using 
the following equation. 
θ = tan-1(h/r) 
Where, h and r are the height and radius of the powder cone 
respectively. 
Bulk density 
Both loose bulk density (LBD) and tapped density (TBD) 
were determined were calculated using the following 
formulas. 
LBD = Powder weight/volume of the packing 
TBD = Powder weight /tapped volume of the packing 
Compressibility index 
 The compressibility index of the granules was determined 
by Carr’s compressibility index. 
Carr’s index (%) = [(TBD – LBD)/TBD] × 100. 
Hausner’s ratio 
Hausner’s ratio is an indirect index of ease of measuring the 
powder flow. It was calculated by the following formula [12-
14]. 
Hausner’s ratio = Tapped density/Bulk density. 
Formulation development of tablets 
Direct compression method 
Different tablets formulations (F1-F8) were prepared by 
direct compression technique. All powders were passed 
through 40 meshes. Required quantities of drug and 
polymers were mixed thoroughly Magnesium stearate was 
added as lubricant. Talc was used as glidant. Lactose was 
used as diluents. Finally the powder mix was subjected to 
compression after mixing uniformly in a polybag. Prior to 
compression, the blends were evaluated for several tests 
[15]. The composition of TRZ floating tablets was shown in 
Table 1. 
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Table 1 Formulation composition of trazodone hydrochloride gastro retentive tablets 
Excipients(mg) F1     F2 F3 F4   F5 F6    F7    F8 
Trazodone 
hydrochloride 
10 10 10 10 10 10 10 10 
HPMC K 15 90 120 - - - - - - 
HPMC K 4 - - 90 120 - -  - 
Xanthan gum - - - - 90 120 45 60 
Guar gum - - - - - - 45 60 
PVP K30 15 15 15 15 15 15 15 15 
Citric acid 5 5 5 5 5 5 5 5 
NaHCO3 20 20 20 20 30 30 30 30 
Mg(C18H35O2)2 5 5 5 5 5 5 5 5 
Talc 5 5 5 5 5 5 5 5 
Lactose 110 80 110 80 110 70 100 70 
Total Weight 250 250 250 250 250 250 250 250 
 
Evaluation of tablets 
All the tablets were evaluated for following different 
parameters which includes; 
General Appearance 
Five tablets from different batches were randomly selected 
and organoleptic properties such as color, odor, taste, shape 
were evaluated. Appearance was judged visually. 
Thickness and diameter 
Thickness and diameter of tablets were determined using 
Vernier caliper. Five tablets from each batch were used, and 
an average value was calculated. 
Hardness 
For each formulation, the hardness of five tablets was 
determined using the Monsanto hardness tester (Cadmach). 
Friability 
The friability of a sample of 10 tablets was measured using a 
Friability tester (Electro Lab).Ten tablets were weighed, 
rotated at 25 rpm for 4 minutes. Tablets were reweighed 
after removal of fines (dedusted) and the percentage of 
weight loss was calculated. 
Uniformity of weight 
Twenty tablets were randomly selected from each batch 
individually weighed, the average weight and standard 
deviation of 20 tablets was calculated. 
Drug content 
Twenty tablets were taken and amount of drug present in 
each tablet was determined. The tablets were crushed in a 
mortar and the powder equivalent to 100mg of drug was 
transferred to 100ml standard flask. The powder was 
dissolved in 50 ml of 0.1 N HCl and made up to volume with 
of 0.1 N HCl. The sample was mixed thoroughly and filtered 
through a 0.45μ membrane filter. The filtered solution was 
diluted suitably and analyzed for drug content by UV 
spectrophotometer at a λmax of 246 nm using of 0.1 N HCl as 
blank. 
In vitro buoyancy studies: 
In vitro buoyancy was determined by floating lag time as per 
the method described by Rosa et al [16]. The tablets were 
separately in a 100 ml glass beaker containing simulated 
gastric fluid (SGF), pH 1.2 as per USP. The time necessary for 
the tablet to increase to the outside and float was determined 
as floating lag time. The experiments were conducted in 
triplicate. Total floating times were measured during in 
vitro dissolution studies. 
Dissolution rate studies 
In vitro drug release of the sample was done using USP-type 
II dissolution apparatus (Paddle type). The dissolution 
medium, 900 ml 0.1N HCl was set into the dissolution flask 
maintaining the temperature of 37±0.50c and rpm of 75. One 
TRZ tablet was set in every container of dissolution 
apparatus. The mechanical assembly was permitted to keep 
running for 10 hours. Sample measuring 5 ml were pulled 
back after each 1 hour up to 10 hours using 10ml pipette. 
The new disintegration medium (370C) was supplanted each 
time with a similar amount of the sample and takes the 
absorbance at 246nm using spectroscopy [17-19]. 
Mathematical treatment of in-vitro release data: The 
quantitative analysis of the qualities got in 
dissolution/release tests is simpler when mathematical 
formulas that express the dissolution comes about as an 
element of a portion of the measurement frames attributes 
are utilized. 
Zero-order kinetics: The pharmaceutical dosage frames 
following this profile release a similar measure of medication 
by unit of time and it is the ideal method of medication 
release keeping in mind the end goal to accomplish a 
pharmacological prolonged action. The following relation 
can, in a simple way, express this model: 
Qt = Qo + Ko t 
where Qt is the amount of drug dissolved in time t, Qo is the 
initial  amount of drug in the solution (most times, Qo=0) and 
Ko is the zero order release constant. 
First-order kinetics: The following relation expresses this 
model: 
 
where Qt is the amount of drug dissolved in time t, Qo is the 
initial  amount of drug in the solution and K1 is the zero 
order release constant. 
Along these lines a graphic of the decimal logarithm of the 
released measure of drug versus time will be linear. The 
pharmaceutical dosage shapes following this dissolution 
profile, for example, those containing water-solvent drugs in 
permeable frameworks, discharge drug in a way that is 
corresponding to the measure of drug staying in its inside, in 
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such way, that the measure of drug released by unit of time 
reduce. 
Higuchi model: Higuchi built up a few theoretical models to 
ponder the arrival of water-solvent and low dissolvable 
medications in semi-strong or potentially strong grids. 
Mathematical expressions were acquired for sedate particles 
scattered in a uniform grid acting as the diffusion media. The 
simplified Higuchi model is expressed as: 
 
Where Q is the amount of drug released in time t and KH is 
the Higuchi dissolution constant. Higuchi model describes 
drug release as a diffusion process based in the Fick’s law, 
square root time dependent. This relation can be utilized to 
portray the drug dissolution from a few kinds of modified 
release pharmaceutical dosage structures, for example, 
transdermal systems and matrix tablets with water-
dissolvable drugs. 
Korsmeyer-Peppas model: Korsmeyer et al. used a simple 
empirical equation to describe general solute release 
behaviour from controlled release polymer matrices:  
 
where Mt/M is fraction of drug released, a is kinetic 
constant, t is release time and n is the diffusional exponent 
for drug release. ’n’ is the slope value of log Mt/M  versus log 
time curve. Peppas stated that the above equation could 
adequately describe the release of solutes from slabs, 
spheres, cylinders and discs, regardless of the release 
mechanism. Peppas used this n value in order to characterize 
different release mechanisms, concluding for values for a 
slab, of n =0.5 for fickian diffusion and higher values of n, 
between 0.5 and 1.0, or n =1.0, for mass transfer following a 
non-fickian model. In case of a cylinder n =0.45 instead of 
0.5, and 0.89 instead of 1.0. This equation can only be used in 
systems with a drug diffusion coefficient fairly concentration 
independent. To the determination of the exponent n the 
portion of the release curve where Mt/M  < 0.6 should only 
be used. To use this equation it is also necessary that release 
occurs in a one-dimensional way and that the system width-
thickness or length-thickness relation be at least 10. A 
modified form of this equation was developed to 
accommodate the lag time (l) in the beginning of the drug 
release from the pharmaceutical dosage form: 
 
When there is the possibility of a burst effect, b, this equation 
becomes: 
 
In the absence of lag time or burst effect, l and b value would 
be zero and only atn is used. This mathematical model, also 
known as Power Law, has been used very frequently to 
describe release from several different pharmaceutical 
modified release dosage forms [20]. 
Stability studies  
The optimized formulation of TRZ were packed in strips of 
0.04 mm thick aluminum foil laminated with poly vinyl 
chloride by strip packing and these packed formulations 
were stored in ICH certified stability chambers (Thermo labs, 
Mumbai) maintained at 40 0C and 75% RH for 6 months. The 
samples were withdrawn periodically and evaluated for their 
floating lag time, content uniformity and for in vitro drug 
release. 
RESULTS AND DISCUSSION 
Solubility of TRZ was freely soluble in methanol and ethanol, 
slightly soluble in 0.1N NaOH, soluble in water, 0.1N HCL and 
6.8 pH phosphate buffers. The melting point of TRZ was 223-
226ºC and λ max of TRZ was found to be 246.0 nm by using 
U.V. spectrophotometer (Labindia-3000+) in linearity range 
5-25 µg/ml.  
Tablet powder blend was subjected to various pre-
compression parameters Table 2. The angle of repose values 
indicates that the powder blend has good flow properties. 
The bulk density and tapped density of all the formulations 
was found to be in the range of 0.489to 0.498 (gm/ml) and 
0.608 to 0.615 showing that the powder has good flow 
properties. The compressibility index and Hauser’s ratio of 
all the formulations was found to be ranging between 18.586 
to 20.488 and 1.228 to1.258  which show that the powder 
has good flow properties. TRZ tablet quality control tests 
such as weight variation, hardness and friability, thickness, 
drug content and drug release studies in different media 
were performed on the compression tablet. All the 
parameters such as weight variation, hardness, friability, 
thickness and drug content were found to be within limits 
Table 3. 
 
Table 2 Result of pre-compression properties of TRZ FGR tablets 
F. Code 
Bulk density 
(gm/ml) 
Tapped density 
(gm/ml) 
Compressibility 
index 
Hausner’s 
ratio 
Trazodone hydrochloride 
F1 0.498 0.612 18.627 1.229 
F2 0.495 0.608 18.586 1.228 
F3 0.497 0.615 19.187 1.237 
F4 0.495 0.613 19.250 1.238 
F5 0.489 0.615 20.488 1.258 
F6 0.492 0.612 19.608 1.244 
F7 0.496 0.615 19.350 1.240 
F8 0.498 0.614 18.893 1.233 
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Table 3 Results of post compression properties of TRZ GRF tablets 
F. code Thickness* 
(mm) 
Hardness* 
(kg/cm2) 
Weight 
variation* 
(mg) 
Friability* 
(%) 
Drug 
content* (%) 
F1 2.85±0.12 5.1±0.2 255±2 0.895±0.012 98.98±0.12 
F2 2.86±0.25 5.2±0.3 249±3 0.856±0.015 98.45±0.25 
F3 2.84±0.32 5.1±0.1 256±4 0.985±0.016 98.65±0.23 
F4 2.86±0.14 5.1±0.2 257±6 0.965±0.014 99.02±0.41 
F5 2.89±0.25 5.3±0.2 259±5 0.845±0.015 98.65±0.21 
F6 2.83±0.23 5.4±0.3 252±7 0.865±0.023 99.06±0.45 
F7 2.81±0.32 5.4±0.1 249±8 0.745±0.032 98.85±0.52 
F8 2.83±0.45 5.2±0.3 248±9 0.658±0.041 99.12±0.41 
 
In the present study 8 formulations with variable 
concentration of polymers (HPMC K4, K 15 guar gum and 
xanthan gum) were prepared by direct compression method 
and evaluated for physicochemical properties. The results of 
buoyancy lag time, total floating time and in vitro drug 
release was given in Table 4, 5 & Fig.2. The results indicated 
that optimizes formulation F7 on immersion in 0.1N HCl at 
37±0.50C tablets immediately and remain buoyant up to 
12hr without disintegration. These 2 factors are essential for 
tablets to acquire density< 1, so that it remains buoyant on 
the gastric fluids. The in vitro drug release data of the 
optimized formulation was subjected to goodness of fit test 
by linear regression analysis according to zero order, first 
order kinetic equation, higuchi’s and korsmeyer’s models in 
order to determine the mechanism of drug release. When the 
regression coefficient values of were compared, it was 
observed that ‘r’ values of first order was maximum i.e. 
0.974 hence indicating drug release from formulations was 
found to follow first order release kinetics Table 6, 7 & Fig. 3, 
4.
  
Table 4 Results of in-vitro buoyancy study of TRZ 
F. Code Floating lag times 
(sec) 
Total floating 
time (hrs) 
F1 36 MT 12 
F2 45 MT 12 
F3 40 MT 12 
F4 36 MT 12 
F5 32 MT 12 
F6 36 MT 12 
F7 35 MT 12 
F8 39 MT 12 
Table 5 In-vitro drug release study of GRF tablets 
Time % Cumulative Drug Release* 
(hr) F1 F2 F3 F4 F5 F6 F7 F8 
0.5 30.25±0.25 29.98±0.32 27.78±0.14 25.65±0.23 32.25±0.23 33.12±0.32 22.32±0.36 20.12±0.25 
1 45.56±0.32 40.56±0.41 39.98±0.25 36.65±0.25 40.23±0.32 39.98±0.12 36.65±0.32 30.45±0.32 
1.5 56.65±0.45 53.65±0.23 50.23±0.32 48.89±0.32 59.98±0.12 60.23±0.25 45.65±0.14 41.32±0.41 
2 89.98±0.65 73.32±0.44 69.98±0.33 65.52±0.14 66.45±0.41 65.45±0.41 55.65±0.25 50.23±0.32 
3 98.89±0.52 85.56±0.33 79.98±0.41 73.32±0.52 80.23±0.25 78.85±0.23 66.65±0.36 56.65±0.52 
4 - 99.12±0.25 86.65±0.45 82.23±0.32 98.89±0.23 89.98±0.32 75.56±0.65 63.32±0.12 
6 - - 98.45±0.65 90.45±0.41 - 96.65±0.65 83.32±0.41 78.89±0.12 
8 - - - 98.85±0.25 - - 91.15±0.23 85.56±0.23 
12 - - - - - - 98.89±0.32 89.98±0.32 
 
 
Fig.2 In-vitro drug release study of GRF tablets 
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Table 6 In-vitro drug release data for optimized formulation F7 
Time (h) 
Square Root 
of Time(h)1/2 
Log Time 
Cumulative*% Drug 
Release 
Log Cumulative 
% Drug Release 
Cumulative %  
Drug Remaining 
Log Cumulative 
% Drug 
Remaining 
0.5 0.707 -0.301 22.32±0.36 1.368 76.64 1.884 
1 1.000 0.000 36.65±0.32 1.426 73.31 1.865 
1.5 1.225 0.176 45.65±0.14 1.589 61.22 1.787 
2 1.414 0.301 55.65±0.25 1.656 54.75 1.738 
3 1.732 0.477 66.65±0.36 1.745 44.44 1.648 
4 2.000 0.602 75.56±0.65 1.838 31.11 1.493 
6 2.449 0.778 83.32±0.41 1.895 21.42 1.331 
8 2.828 0.903 91.15±0.23 1.954 10.02 1.001 
12 3.464 1.079 98.89±0.32 1.995 1.11 0.045 
 
Table 7 Regression analysis data of TRZ floating tablets 
Batch 
Zero Order First Order 
R² R² 
F7 0.820 0.974 
 
CONCLUSION  
Trazodone Hydrochloride floating tablets were successfully 
formulated by floating technique. The optimized formulation 
(F7) was selected on the basis of in vitro buoyancy and in 
vitro drug release. The addition of gel forming agent and gas 
generating agent was essential to achieve in vitro buoyancy. 
The results of the in vitro drug release and in vitro buoyancy 
study showed that the optimized formulation (F7) sustained 
the drug release (98.89) up to 12 hrs and remained buoyant 
for >12 hrs. Optimized formulation (F7) does not show any 
significant change in physical appearance, floating properties 
and drug release after storage at 40°C/75% RH and stable 
for 6 months. 
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